Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2016

Feb 18, 2016

34238_dirs_2016-02-18_49b93639-277f-4dae-8a29-97a61248e83d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2016-02-16

Reporting Person: CHAPMAN KAREN B. (Vice President of Research)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-02-16 Option to Purchase Common Stock $3.06 A 60000 Acquired 2026-02-15 Common Stock (60000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option to Purchase Common Stock $2.20 2025-01-08 Common Stock (100000) 100000 Direct
Option to Purchase Common Stock $1.50 2018-03-31 Common Stock (200000) 200000 Direct
Option to Purchase Common Stock $2.20 2025-01-08 Common Stock (125000) 125000 Indirect
Option to Purchase Common Stock $1.34 2020-12-28 Common Stock (250000) 250000 Indirect

Footnotes

F1: One quarter of the options shall vest on February 15, 2017, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.

F2: One quarter of the options vested on January 8, 2016 upon the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.

F3: 1/48th of the number of options vested and became exercisable at the end of each full month of employment after the date of grant on April 1, 2011.

F4: One quarter of the options granted to Michael West vested on January 8, 2016, and the balance shall vest in 36 monthly installments from the first anniversary of the date of grant. Dr. West and Dr. Chapman are husband and wife.

F5: 1/48th of the number of options granted to Michael West vested and became exercisable at the end of each full month after the date of grant on December 29, 2010. Dr. West and Dr. Chapman are husband and wife.